Rabbit anti-thymocyte globulin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Kidney TransplantSickle Cell DiseaseToxicityMemorySevere Aplastic AnemiaKidney Transplant RejectionRenal Transplant Failure and Rejection

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

1

Rabbit anti-thymocyte globulin

Sanofi

Phase 2

172

Nulojix

Bristol-Myers Squibb

Preclinical

163

Simulect

Novartis

Preclinical

154

Medrol

Pfizer

Preclinical

125

Zinbryta

Roche

Preclinical

66

Zemplar

AbbVie

Preclinical

27

Radicava

Shionogi

Preclinical

18

Cysteine Hydrochloride

Novartis

Preclinical

19

Sensipar

Amgen

Preclinical

110

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Severe Aplastic Anemia3 trials

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Completed·MMichael Pulsipher·N/A·NCT02845596·40 enrolled

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Active, not recruiting·—·Phase 3·NCT05600426·53 enrolled

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

Completed·Novartis·Phase 2·NCT04328727·36 enrolled

Allogeneic Stem Cell Transplantation1 trial

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Completed·—·Phase 2/3·NCT01019876·38 enrolled

Transplantation1 trial

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Non-malignant Disorders1 trial

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03980769·40 enrolled

Sickle Cell Disease1 trial

A Blood Stem Cell Transplant for Sickle Cell Disease

Active, not recruiting·—·Phase 1·NCT03249831·3 enrolled

10 more indications

Stem Cell Transplant1 trial

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00230035

Immunosuppression1 trial

Phase I/II Thymus Transplantation With Immunosuppression #950

Completed·SSumitomo Pharma Switzerland GmbH·Phase 1/2·NCT00579527·14 enrolled

Renal Transplant Recipients1 trial

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Completed·Astellas·Phase 4·NCT00113269·501 enrolled

Toxicity1 trial

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

Memory1 trial

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Recruiting·WWashington University School of Medicine·Phase 1/2·NCT06158828·68 enrolled

Treatment1 trial

Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.

Active, not recruiting·VVastra Gotaland Region·N/A·NCT02936505·249 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00448357·54 enrolled

Renal Transplant Failure and Rejection1 trial

Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids

Recruiting·NNefro Avillion Clinical Development, LLC·Phase 2·NCT07508787·120 enrolled

Kidney Transplant Rejection1 trial

A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

Recruiting·Sanofi·Preclinical·NCT07412470·526 enrolled

Unspecified1 trial

Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

Unknown status·MMedical University of Silesia·N/A·NCT05199103·20 enrolled

Details

Drug Info

Related News